Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 461

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Pathophysiology, Diagnosis and Management of Peripartum Cardiomyopathy: A Position Statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Open access
Bauersachs, Johann, König, Tobias, van der Meer, Peter, Petrie, Mark C., Hilfiker-Kleiner, Denise, Mbakwem, Amam, Hamdan, Righab, Jackson, Alice M., Forsyth, Paul, de Boer, Rudolf A., Mueller, Christian, Lyon, Alexander R., Lund, Lars H., Piepoli, Massimo F., Heymans, Stephane, Chioncel, Ovidiu, Anker, Stefan D., Ponikowski, Piotr, Seferovic, Petar M., Johnson, Mark R., Mebazaa, Alexandre, Sliwa, Karen·2019·European Journal of Heart Failure

Abstract

Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition typically presenting as heart failure with reduced ejection fraction (HFrEF) in the last month of pregnancy or in the months following delivery in women without another known cause of heart failure. This updated position statement summarizes the knowledge about pathophysiological mechanisms, risk factors, clinical presentation, diagnosis and management of PPCM. As shortness of breath, fatigue and leg oedema are common in the peripartum period, a high index of suspicion is required to not miss the diagnosis. Measurement of natriuretic peptides, electrocardiography and echocardiography are recommended to promptly diagnose or exclude heart failure/PPCM. Important differential diagnoses include pulmonary embolism, myocardial infarction, hypertensive heart disease during pregnancy, and pre-existing heart disease. A genetic contribution is present in up to 20% of PPCM, in particular titin truncating variant. PPCM is associated with high morbidity and mortality, but also with a high probability of partial and often full recovery. Use of guideline-directed pharmacological therapy for HFrEF is recommended in all patients respecting contraindications during pregnancy/lactation. The oxidative stress-mediated cleavage of the hormone prolactin into a cardiotoxic fragment has been identified as a driver of PPCM pathophysiology. Pharmacological blockade of prolactin release using bromocriptine as a disease-specific therapy in addition to standard therapy for heart failure treatment has shown promising results in two clinical trials. Thresholds for devices (implantable cardioverter-defibrillators, cardiac resynchronization therapy and implanted long-term ventricular assist devices) are higher in PPCM than in other conditions because of the high rate of recovery. The important role of education and counselling around contraception and future pregnancies is emphasised.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.1493

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 461

Metadata

Authors
Bauersachs, J., König, T., van der Meer, P., Petrie, M. C., Hilfiker-Kleiner, D., Mbakwem, A., Hamdan, R., Jackson, A. M., Forsyth, P., de Boer, R. A., Mueller, C., Lyon, A. R., Lund, L. H., Piepoli, M. F., Heymans, S., Chioncel, O., Anker, S. D., Ponikowski, P., Seferovic, P. M., Johnson, M. R., Mebazaa, A., & Sliwa, K.
Venue
European Journal of Heart Failure
Published
2019-06-27
Volume
21
Issue
7
Pages
827-843
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2954764069
Cited by
461
References
72
FWCI
28.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.